PSAT1 Antibody, Biotin conjugated

Code CSB-PA018838LD01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) PSAT1 Polyclonal antibody
Uniprot No.
Target Names
PSAT1
Alternative Names
EC 2.6.1.52 antibody; Endometrial progesterone induced protein antibody; EPIP antibody; MGC1460 antibody; NLS2 antibody; Phosphohydroxythreonine aminotransferase antibody; phosphoserine aminotransferase 1 antibody; Phosphoserine aminotransferase antibody; PSA antibody; PSAT antibody; Psat1 antibody; PSATD antibody; SERC_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Phosphoserine aminotransferase protein (104-206AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Biotin
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalyzes the reversible conversion of 3-phosphohydroxypyruvate to phosphoserine and of 3-hydroxy-2-oxo-4-phosphonooxybutanoate to phosphohydroxythreonine.
Gene References into Functions
  1. PSAT1 protein and mRNA levels were significantly associated to poor outcome to tamoxifen treatment of breast cancer. PMID: 28522855
  2. PSAT1, which is overexpressed in ER-negative breast cancers, is activated by ATF4 and promotes cell cycle progression via regulation of the GSK3beta/beta-catenin/cyclin D1 pathway. PMID: 29216929
  3. Data suggest that phosphoserine aminotransferase 1 (PSAT1) may be a promising anticancer therapeutic target. . PMID: 27372650
  4. High expression of PSAT is associated with Colon Cancer. PMID: 26439504
  5. PSAT1 expression positively correlates with the levels of phosphorylated cyclin D1 in non-small cell lung cancer. PMID: 25142862
  6. phosphoserine aminotransferase deficiency is associated with Neu-Laxova syndrome. PMID: 25152457
  7. we propose an idea that PSAT1 may be implicated in altered serine metabolism and schizophrenia spectrum conditions. PMID: 20955740
  8. nucleotide sequence and enzymatic activity of two isoforms generated by alternative splicing; differential expression depending upon tissue specificity and cellular proliferation status PMID: 12633500
  9. Overexpression of phosphoserine aminotransferase is associated with colorectal cancer development PMID: 18221502

Show More

Hide All

Involvement in disease
Phosphoserine aminotransferase deficiency (PSATD); Neu-Laxova syndrome 2 (NLS2)
Protein Families
Class-V pyridoxal-phosphate-dependent aminotransferase family, SerC subfamily
Tissue Specificity
Expressed at high levels in the brain, liver, kidney and pancreas, and very weakly expressed in the thymus, prostate, testis and colon.
Database Links

HGNC: 19129

OMIM: 610936

KEGG: hsa:29968

STRING: 9606.ENSP00000365773

UniGene: Hs.494261

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*